secwatch.observer — SEC 8-K summary
======================================

Issuer:     IRONWOOD PHARMACEUTICALS INC (IRWD)
CIK:        0001446847
Form:       8-K
Filed at:   2025-02-27T23:59:59+00:00
Accession:  0001104659-25-017774
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ironwood FY2024 revenue $351M, net income positive; apraglutide NDA rolling initiated
--------------------------------------------------------------------------------

- Total revenue $90.5M in Q4 and $351.4M for FY2024, down 23% YoY from $442.7M in FY2023.
- GAAP net income $1.8M in FY2024 vs. loss of $1.0B in FY2023 (prior year included impairment).
- Adjusted EBITDA $100.6M for FY2024, a significant improvement from $(884.8)M in FY2023.
- LINZESS prescription demand grew 11% YoY in FY2024; company achieved 2024 financial guidance.
- Rolling NDA submission for apraglutide (SBS) initiated, on track for completion in Q3 2025; OLE data showed 27 patients achieving enteral autonomy.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1446847/000110465925017774/0001104659-25-017774-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1446847/000110465925017774/tm257621d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-017774

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer